Compare Biogen Inc (BIIB) vs Cloudflare Inc (NET) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Cloudflare (NET) trades at $269.45, up 0.39% on the day, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth is strong, reaching $2.17 billion in 2025, but profitability remains a challenge with a net income margin of -3.72%. Recent news highlights strategic AI partnerships and product launches, including a research pilot with OpenAI and the introduction of Precursor for bot management.

The outlook for NET is cautiously optimistic, driven by AI infrastructure demand and cybersecurity tailwinds, but high valuation multiples and persistent losses pose risks. Analyst consensus is strongly bullish with a 72.5% buy rating, though the current price exceeds the average target of $257.43. Investors should weigh growth potential against profitability concerns and competitive pressures in the cloud sector.